General Information of Drug (ID: DMZMCB1)

Drug Name
GW274150 Drug Info
Synonyms
GW274150; GW-274150; UNII-0ZZF1V8G63; 0ZZF1V8G63; CHEMBL114551; SCHEMBL120693; L-Homocysteine, S-(2-((1-iminoethyl)amino)ethyl)-; GTPL9849; ZINC2004483; BDBM50086467; AKOS030526714; DB12237; CS-5419; HY-12119; GW-274150;GW 274150; [2-[(1-iminoethyl) amino]ethyl]-L-homocysteine; (S)-4-(2-Acetimidoylamino-ethylsulfanyl)-2-amino-butyric acid; (2S)-2-amino-4-[2-(1-aminoethylideneamino)ethylsulfanyl]butanoic acid
Indication
Disease Entry ICD 11 Status REF
Asthma CA23 Phase 2 [1]
Cross-matching ID
PubChem CID
9797017
CAS Number
CAS 210354-22-6
TTD Drug ID
DMZMCB1

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Curcumin DMQPH29 Solid tumour/cancer 2A00-2F9Z Phase 3 [3]
SD-6010 DM9DEYL Osteoarthritis FA00-FA05 Phase 3 [4]
MPL-S DMNDCFY Endotoxic shock 1G41 Phase 3 [5]
Pimagedine HCl DMPWH30 Diabetic kidney disease GB61.Z Phase 2/3 [6]
BXT-51072 DMD8GNB Cardiovascular disease BA00-BE2Z Phase 2 [7]
HP-228 DMNZ35F Postoperative pain MG30-MG3Z Phase 2 [8]
CR-3294 DMHJEZS Diarrhea ME05.1 Phase 2 [9]
KD-7040 DME1WV2 Pain MG30-MG3Z Phase 2 [10]
LT-1951 DM5N04G Coronary artery disease BA80 Phase 1/2 [11]
Aminoguanidine DMJQDUC Diabetic retinopathy 9B71.0 Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Nitric-oxide synthase inducible (NOS2) TTF10I9 NOS2_HUMAN Modulator [2]

References

1 ClinicalTrials.gov (NCT00370435) Study Of 90mg Of GW274150 In Subjects Over 50 Years, Who Have Rheumatoid Arthritis (RA). U.S. National Institutes of Health.
2 GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int. 2003 Mar;63(3):853-65.
3 A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8.
4 A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee. Ann Rheum Dis. 2013 Feb;72(2):187-95.
5 Lipopolysaccharide and monophosphoryl lipid A differentially regulate interleukin-12, gamma interferon, and interleukin-10 mRNA production in murine macrophages. Infect Immun. 1997 Aug;65(8):3239-47.
6 Nitric oxide associated with iNOS expression inhibits acetylcholinesterase activity and induces memory impairment during acute hypobaric hypoxia. Brain Res. 2008 Sep 16;1230:138-49.
7 Shear stress induces iNOS expression in cultured smooth muscle cells: role of oxidative stress. Am J Physiol Cell Physiol. 2000 Dec;279(6):C1880-8.
8 HP-228, a novel synthetic peptide, inhibits the induction of nitric oxide synthase in vivo but not in vitro. J Pharmacol Exp Ther. 1995 Nov;275(2):584-91.
9 Efficacy of CR3294, a new benzamidine derivative, in the prevention of 5-fluorouracil-induced gastrointestinal mucositis and diarrhea in mice. Cancer Chemother Pharmacol. 2010 October; 66(5): 819-827.
10 WO patent application no. 2014,0214,08, Method for treating cancer by anticancer agent co-administration.
11 Critical role of L-arginine in endothelial cell survival during oxidative stress. Circulation. 2003 May 27;107(20):2607-14.
12 Inhibitory effects of aminoguanidine on thyroid follicular carcinoma development in inflamed capsular regions of rats treated with sulfadimethoxine... Cancer Sci. 2009 Oct;100(10):1794-800.